

Autologous Stem Cell & Non-stem Cell Therapies Market by Type (CAR-T, Tumor Infiltrating Lymphocyte), Indication (Cancer, Musculoskeletal, Dermatology), Source (T-Cells, Mesenchymal Stem Cell), End User (Hospital) - Global Forecast to 2029

Market Report | 2024-06-07 | 295 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The autologous stem cell & non-stem cell therapies market is projected to reach USD 22.2 billion by 2029 from USD 5.5 billion in 2024, at a CAGR of 32.3% during the forecast period. The growth of this market is driven by several factors such as the growing regulatory approvals for autologous CAR T cell-based therapies, increasing R&D investments for the development of autologous cell therapies, and an increase in the demand for personalized medicines.

"The autologous stem cell & non-stem cell therapies market growth for Autologous non-stem cell therapies can be attributed to the increasing number of cancer cases leading to increased demand for substantial treatment option."

The autologous stem cell & non-stem cell therapies market, based on type segment is further segmented into autologous stem cell therapies and autologous non-stem cell therapies. The autologous non-stem cell therapies sub-segment is further divided into CAR T cell therapies, Tumor Infiltrating Lymphocyte (TIL), and other therapies (of skin grafts, others). The autologous non-stem cell therapies hold the dominant share due to the rise in global cancer cases accelerating the demand for the development of effective cancer treatment solutions such as autologous non-stem-cell-based therapies, which are increasingly valued in the market due to the rising number of regulatory approvals for these therapies and growing number of cancer patients seeking viable treatment alternatives.

"By Indications, the cancer indication subsegment accounted for the largest share of the autologous stem cell & non-stem cell therapies market in 2023."

The indication segment is further segmented into cancer indications and non-cancer indications. In 2023, the cancer indications subsegment accounted for the largest share of the indication segment due to the rising number of global cancer cases, and a growing demand for the development of effective and efficient cancer therapeutics such as autologous CAR T cell therapies, that

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

are shown to be effective for treating various forms of cancer such as multiple myeloma and various types of lymphoma.

"North American region is expected to register the highest CAGR in the autologous stem cell & non-stem cell therapies market." The market for autologous stem cell & non-stem cell therapies in North America is estimated to grow at the highest rate during the forecast period. The rising academic and organizational interest in autologous stem cell and non-stem cell-based research, complemented by the North American healthcare sector's expansion and the rising approvals and utilization of autologous stem cell and non-stem cell-based therapies for cancer and other chronic diseases are factors that will aid the market growth in North America. North America also has an established pharmaceutical manufacturing infrastructure and the presence of prominent players in the autologous stem cell & non-stem cell therapies market such as Gilead Sciences, Inc. (US), Bristol-Myers Squibb Company (US), Johnson & Johnson (US) among others which further supports the leadership position of this region.

The primary interviews conducted for this report can be categorized as follows:

- By Respondent: Supply Side- 70% and Demand Side - 30%
- By Designation: C Level Executives- 55%, CXOs, and Director level - 20%, and Others- 25%
- By Region: North America -50%, Europe - 20%, Asia-Pacific -20%, RoW -10%

List of Companies Profiled in the Report

- Gilead Sciences, Inc. (US)
- Bristol-Myers Squibb Company (US)
- Johnson & Johnson (US)
- Vericel Corporation (US)
- Novartis AG (Switzerland)
- W (Cayman) Therapeutics Co. Ltd (China)
- APAC Biotech (India)
- Regrow Biosciences Pvt Ltd. (India)
- Healiva SA (Switzerland)

Note: The above list is in exhaustive

Research Coverage:

This report provides a detailed picture of the autologous stem cell & non-stem cell therapies market. It aims to estimate the market's size and future growth potential across different segments such as the type, indication, source, end user, and region. The report also includes an in-depth competitive analysis of the key market players and their company profiles, recent developments, key market strategies, funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the autologous stem cell & non-stem cell therapies market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall autologous stem cell & non-stem cell therapies market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide information on the key market drivers, restraints, challenges, trends, and opportunities.

The report provides insights on the following pointers:

- Analysis of key drivers (e.g., increasing government approvals for various autologous cell-based therapies, increasing investments and funding towards the development of autologous cell-based therapies and the growing number of clinical trials involving autologous stem and non-stem cells), restraints (e.g., uptake of allogeneic cell-based therapies as substitutes), opportunities (e.g, outsourcing manufacturing of cell therapy and focus on closed automated systems), and challenges (e.g, regulatory complications and reimbursement challenges and issues in scalable manufacturing) are influencing the growth of the autologous stem cell & non-stem cell therapies market.
- Product Approvals: Detailed insights on newly approved products of the autologous stem cell & non-stem cell therapies market.
- Market Development: Comprehensive information about lucrative markets - the report analyses the autologous stem cell &

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

non-stem cell therapies market across varied regions.

-□Market Diversification: Exhaustive information about new products, recent developments, and investments in the autologous stem cell & non-stem cell therapies market.

-□Pipeline Analysis: Comprehensive information about products under clinical trials.

-□Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players including Gilead Sciences, Inc. (US), Bristol-Myers Squibb Company (US), Johnson & Johnson (US), Vericel Corporation (US), Novartis AG (Switzerland), JW (Cayman) Therapeutics Co. Ltd (China), Iovance Biotherapeutics, Inc. (US), APAC Biotech (India), Regrow Biosciences Pvt Ltd. (India), healiva SA (Switzerland), Green Cross Holdings Co., Ltd. (GC Cell) (Republic of Korea)), Sanpower Group Co., Ltd. (Dendreon Pharmaceuticals Llc. (China), Tegoscience (South Korea), ImmunoACT (India), CARsgen Therapeutics Holdings Limited (China), IASO Biotherapeutics (China), Pharmicell Co., Ltd (South Korea), Anterogen.Co.,Ltd. (South Korea) among others offering autologous stem cell & non-stem cell-based therapeutic products.

Table of Contents:

1□INTRODUCTION□43

1.1□STUDY OBJECTIVES□43

1.2□MARKET DEFINITION□43

1.2.1□INCLUSIONS & EXCLUSIONS□44

1.3□MARKET SCOPE□44

1.3.1□MARKET SEGMENTATION□44

1.3.2□REGIONAL SEGMENTATION□45

FIGURE 1□REGIONS COVERED□45

1.3.3□YEARS CONSIDERED□45

1.3.4□CURRENCY CONSIDERED□46

1.4□STAKEHOLDERS□46

1.5□SUMMARY OF CHANGES□46

1.6□RECESSION IMPACT□47

2□RESEARCH METHODOLOGY□48

2.1□RESEARCH DATA□48

FIGURE 2□RESEARCH DESIGN□48

2.1.1□SECONDARY DATA□49

2.1.2□PRIMARY DATA□50

FIGURE 3□BREAKDOWN OF PRIMARIES: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS□50

2.2□MARKET SIZE ESTIMATION□51

FIGURE 4□AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: MARKET SIZE ESTIMATION FOR SUPPLY-SIDE ANALYSIS, 2023□51

FIGURE 5□AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: REVENUE SHARE ANALYSIS, 2023□52

FIGURE 6□GILEAD SCIENCES, INC.: REVENUE SHARE ANALYSIS, 2023□52

2.3□PRIMARY INSIGHTS□54

FIGURE 7□VALIDATION FROM PRIMARY EXPERTS□54

2.3.1□SEGMENTAL ASSESSMENT□54

FIGURE 8□MARKET SIZE ESTIMATION: TOP-DOWN APPROACH□54

2.4□GROWTH FORECAST□55

FIGURE 9□AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: CAGR PROJECTIONS (2024-2029)□56

FIGURE 10□GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES□56

2.5□VOLUME ESTIMATION□57

2.6□MARKET BREAKDOWN & DATA TRIANGULATION□58

FIGURE 11□DATA TRIANGULATION METHODOLOGY□58

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

2.7	STUDY ASSUMPTIONS	59
2.8	RISK ANALYSIS	59
TABLE 1	AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: RISK ASSESSMENT ANALYSIS	59
2.9	RECESSION IMPACT ANALYSIS	59
TABLE 2	GLOBAL INFLATION RATE PROJECTIONS, 2021-2028 (% GROWTH)	59
3	EXECUTIVE SUMMARY	61
FIGURE 12	AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)	61
FIGURE 13	AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2024 VS. 2029 (USD MILLION)	62
FIGURE 14	AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2024 VS. 2029 (USD MILLION)	62
FIGURE 15	AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2024?2029	63
FIGURE 16	GEOGRAPHICAL SNAPSHOT OF AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET	64
4	PREMIUM INSIGHTS	65
4.1	AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET OVERVIEW	65
FIGURE 17	RIISING REGULATORY APPROVALS FOR CAR T-CELL THERAPIES TO DRIVE MARKET	65
4.2	NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE AND COUNTRY (2023)	66
FIGURE 18	AUTOLOGOUS NON-STEM CELL THERAPIES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2023	66
4.3	AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SHARE, BY SOURCE, 2024 VS. 2029	66
FIGURE 19	T-CELLS SOURCE SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD	66
4.4	AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SHARE, BY INDICATION, 2023	67
FIGURE 20	CANCER INDICATION SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE IN 2023	67
4.5	AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES	67
FIGURE 21	ASIA PACIFIC REGION TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD	67
5	MARKET OVERVIEW	68
5.1	INTRODUCTION	68
5.2	MARKET DYNAMICS	68
FIGURE 22	AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES	68
TABLE 3	AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: IMPACT ANALYSIS	69
5.2.1	DRIVERS	69
5.2.1.1	Rising approvals for CAR T-cell therapies	69
TABLE 4	APPROVED AUTOLOGOUS CAR T-CELL THERAPIES	70
5.2.1.2	Increasing R&D investments in autologous therapeutics	71
5.2.1.3	Increasing demand for personalized medicine	71
5.2.2	RESTRAINTS	72
5.2.2.1	Uptake of allogeneic cell-based therapies as substitutes	72
5.2.3	OPPORTUNITIES	73
5.2.3.1	Rising outsourcing of manufacturing activities	73
5.2.3.2	Adoption of closed automated systems	73
5.2.4	CHALLENGES	74
5.2.4.1	Stringent regulatory guidelines and reimbursement challenges	74
5.2.4.2	Issues associated with scalable manufacturing	74
5.3	SUPPLY CHAIN ANALYSIS	75
FIGURE 23	SUPPLY CHAIN ANALYSIS: DIRECT DISTRIBUTION STRATEGY PREFERRED BY PROMINENT COMPANIES	76
5.4	TECHNOLOGY ANALYSIS	76
5.4.1	KEY TECHNOLOGIES	76
5.4.1.1	Genome editing	76
5.4.1.2	Synthetic biology	77

5.4.2	COMPLEMENTARY TECHNOLOGIES	77
5.4.2.1	Process analytical technology (PAT)	77
5.4.2.2	Point-of-care manufacturing	77
5.5	VALUE CHAIN ANALYSIS	78
FIGURE 24	VALUE CHAIN ANALYSIS-MAXIMUM VALUE IS ADDED DURING THERAPY MANUFACTURING PHASE	79
5.6	PRICING ANALYSIS	80
TABLE 5	AVERAGE SELLING PRICE FOR LEADING AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPEUTIC DRUGS	80
TABLE 6	AVERAGE SELLING PRICE FOR MAJOR AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPEUTIC DRUGS, BY REGION	81
5.7	ECOSYSTEM ANALYSIS	81
5.7.1	ROLE IN ECOSYSTEM	82
5.8	TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES	83
FIGURE 26	REVENUE SHIFT AND NEW REVENUE POCKETS FOR AUTOLOGOUS STEM CELL AND NON-STEM CELL THERAPY MARKET MANUFACTURERS	83
5.9	PATENT ANALYSIS	84
5.9.1	PATENT ANALYSIS: AUTOLOGOUS CAR-T THERAPIES	84
FIGURE 27	PATENT APPLICATIONS FOR AUTOLOGOUS CAR-T THERAPIES, JANUARY 2013-OCTOBER 2023	84
5.9.2	PATENT ANALYSIS: TIL THERAPY	85
FIGURE 28	PATENT APPLICATIONS FOR TIL THERAPIES, JANUARY 2013-OCTOBER 2023	85
5.10	KEY CONFERENCES & EVENTS, 2024?2025	86
TABLE 7	AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: LIST OF CONFERENCES & EVENTS	86
5.11	REGULATORY LANDSCAPE	88
5.11.1	REGULATORY ANALYSIS	88
5.11.2	NORTH AMERICA	88
5.11.2.1	US	88
5.11.2.2	Canada	88
5.11.3	EUROPE	89
5.11.3.1	Germany	89
5.11.3.2	UK	89
5.11.3.3	Rest of Europe	90
5.11.4	ASIA PACIFIC	90
5.11.4.1	China	90
5.11.4.2	Japan	91
5.11.4.3	South Korea	91
5.11.4.4	Australia	92
5.11.4.5	Rest of Asia Pacific	92
5.11.5	REGULATORY BODIES AND ORGANIZATIONS	92
TABLE 8	NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	93
TABLE 9	EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	93
TABLE 10	ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	94
TABLE 11	LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	95
TABLE 12	MIDDLE EAST & AFRICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	95
5.12	PORTER'S FIVE FORCES ANALYSIS	96
FIGURE 29	AUTOLOGOUS STEM CELL & NON-STEM CELL MARKET: PORTER'S FIVE FORCE ANALYSIS	96
TABLE 13	PORTER'S FIVE FORCES ANALYSIS	96
5.12.1	DEGREE OF COMPETITION	97
5.12.2	BARGAINING POWER OF SUPPLIERS	97

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.12.3	BARGAINING POWER OF BUYERS	97
5.12.4	THREAT OF SUBSTITUTES	97
5.12.5	THREAT OF NEW ENTRANTS	98
5.13	KEY STAKEHOLDERS & BUYING CRITERIA	98
FIGURE 30	INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER	98
5.14	KEY BUYING CRITERIA	99
5.14.1	BUYING CRITERIA OF END USERS FOR AUTOLOGOUS STEM CELL AND NON-STEM CELL THERAPEUTIC PRODUCTS	99
5.14.2	BUYING CRITERIA FOR AUTOLOGOUS STEM CELL AND NON-STEM CELL THERAPEUTIC PRODUCTS, BY END USER	99
5.15	INVESTMENT AND FUNDING SCENARIO	100
5.16	CASE STUDY ANALYSIS	102
5.16.1	CASE STUDY 1	102
5.16.1.1	Comparative Analysis of Cupistem Efficacy in Treatment of Crohn's Perianal Fistulas	102
5.16.2	CASE STUDY 2	102
5.16.2.1	Evaluating Lenzumestrocel (Neuronata-R) in Amyotrophic Lateral Sclerosis: The ALSUMMIT Phase III Trial Protocol	102
5.16.3	CASE STUDY 3	103
5.16.3.1	Stemirac Stem Cell Therapy for Traumatic Spinal Cord Injury	103
5.16.4	CASE STUDY 4	103
5.16.4.1	Efficacy and Safety of Holoclar in Limbal Stem Cell Deficiency	103
6	AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE	104
6.1	INTRODUCTION	105
TABLE 14	AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)	105
TABLE 15	AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (UNITS)	105
6.2	AUTOLOGOUS STEM CELL THERAPIES	105
6.2.1	RIISING INCIDENCE OF CHRONIC DISEASES TO DRIVE MARKET	105
TABLE 16	AUTOLOGOUS STEM CELL THERAPIES MARKET, BY REGION, 2022-2029 (USD MILLION)	106
TABLE 17	NORTH AMERICA: AUTOLOGOUS STEM CELL THERAPIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	106
TABLE 18	EUROPE: AUTOLOGOUS STEM CELL THERAPIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	107
TABLE 19	ASIA PACIFIC: AUTOLOGOUS STEM CELL MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	107
TABLE 20	LATIN AMERICA: AUTOLOGOUS STEM CELL THERAPIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	108
TABLE 21	MIDDLE EAST: AUTOLOGOUS STEM CELL MARKET, BY REGION, 2022-2029 (USD MILLION)	108
TABLE 22	GCC COUNTRIES: AUTOLOGOUS STEM CELL MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	108
6.3	AUTOLOGOUS NON-STEM CELL THERAPIES	109
TABLE 23	AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)	109
TABLE 24	AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY REGION, 2022-2029 (USD MILLION)	109
TABLE 25	NORTH AMERICA: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	110
TABLE 26	EUROPE: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	110
TABLE 27	ASIA PACIFIC: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	111
6.4	CAR T-CELL THERAPIES	111
6.4.1	GROWING APPROVAL OF AUTOLOGOUS CAR T-CELL THERAPIES TO BOOST GROWTH	111
TABLE 28	CAR T-CELL THERAPIES MARKET, BY REGION, 2022-2029 (USD MILLION)	112
TABLE 29	NORTH AMERICA: CAR T-CELL THERAPIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	112
TABLE 30	EUROPE: CAR T-CELL THERAPIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	113
TABLE 31	ASIA PACIFIC: CAR T-CELL THERAPIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	113
6.5	TUMOR-INFILTRATING LYMPHOCYTES (TILS)	113
6.5.1	EMERGING POTENTIAL OF TIL IN CANCER TREATMENT TO BOOST DEMAND	113
TABLE 32	TUMOR-INFILTRATING LYMPHOCYTES MARKET, BY REGION, 2022-2029 (USD MILLION)	114
TABLE 33	NORTH AMERICA: TUMOR-INFILTRATING LYMPHOCYTES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	114

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

7	AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION	115
7.1	INTRODUCTION	116
TABLE 34	AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022-2029 (USD MILLION)	116
7.2	CANCER INDICATION	116
7.2.1	RIISING INCIDENCE OF CANCER AND GROWING DEMAND FOR THERAPEUTICS TO DRIVE MARKET	116
TABLE 35	AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKEY FOR CANCER INDICATIONS, BY REGION, 2022-2029 (USD MILLION)	117
TABLE 36	NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR CANCER INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)	117
TABLE 37	EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR CANCER INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)	118
TABLE 38	ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR CANCER INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)	118
7.3	MUSCULOSKELETAL INDICATION	118
7.3.1	GROWING INCIDENCE OF OSTEOARTHRITIS TO DRIVE MARKET	118
TABLE 39	AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MUSCULOSKELETAL INDICATIONS, BY REGION, 2022-2029 (USD MILLION)	119
TABLE 40	NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MUSCULOSKELETAL INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)	119
TABLE 41	EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MUSCULOSKELETAL INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)	120
TABLE 42	ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MUSCULOSKELETAL INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)	120
TABLE 43	LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MUSCULOSKELETAL INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)	121
TABLE 44	MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MUSCULOSKELETAL INDICATIONS, BY REGION, 2022-2029 (USD MILLION)	121
TABLE 45	GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MUSCULOSKELETAL INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)	121
7.4	DERMATOLOGY INDICATION	122
7.4.1	INCREASING PREVALENCE OF SKIN DISORDERS TO SUPPORT MARKET GROWTH	122
TABLE 46	AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR DERMATOLOGICAL INDICATIONS, BY REGION, 2022-2029 (USD MILLION)	122
TABLE 47	NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR DERMATOLOGICAL INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)	123
TABLE 48	EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR DERMATOLOGICAL INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)	123
TABLE 49	ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR DERMATOLOGICAL INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)	123
TABLE 50	LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR DERMATOLOGICAL INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)	124
TABLE 51	MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR DERMATOLOGICAL INDICATIONS, BY REGION, 2022-2029 (USD MILLION)	124
TABLE 52	GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR DERMATOLOGICAL INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)	124
7.5	OTHER INDICATIONS	125
TABLE 53	AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR OTHER INDICATIONS, BY REGION, 2022-2029 (USD	

MILLION)125

TABLE 541NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)125

TABLE 551EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)126

TABLE 561ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)126

TABLE 571LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)127

TABLE 581MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR OTHER INDICATIONS, BY REGION, 2022-2029 (USD MILLION)127

TABLE 591GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)127

81AUTOLOGOUS STEM CELL AND NON-STEM CELL THERAPIES MARKET, BY SOURCE128

8.11INTRODUCTION128

TABLE 601AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022-2029 (USD MILLION)128

8.21T-CELLS128

8.2.11GROWING ADOPTION OF CAR T-CELL THERAPIES TO DRIVE MARKET128

TABLE 611AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR T-CELLS, BY REGION, 2022-2029 (USD MILLION)129

TABLE 621NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR T-CELLS, BY COUNTRY, 2022-2029 (USD MILLION)129

TABLE 631EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR T-CELLS, BY COUNTRY, 2022-2029 (USD MILLION)130

TABLE 641ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR T-CELLS, BY COUNTRY, 2022-2029 (USD MILLION)130

8.31MESENCHYMAL STEM CELLS131

8.3.11HIGH UPTAKE IN DEVELOPMENT OF AUTOLOGOUS THERAPIES TO SUPPORT MARKET GROWTH131

TABLE 651AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MESENCHYMAL STEM CELLS, BY REGION, 2022-2029 (USD MILLION)131

TABLE 661NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MESENCHYMAL STEM CELLS, BY COUNTRY, 2022-2029 (USD MILLION)132

TABLE 671EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MESENCHYMAL STEM CELLS, BY COUNTRY, 2022-2029 (USD MILLION)132

TABLE 681ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MESENCHYMAL STEM CELLS, BY COUNTRY, 2022-2029 (USD MILLION)133

TABLE 691LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MESENCHYMAL STEM CELLS, BY COUNTRY, 2022-2029 (USD MILLION)133

TABLE 701MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MESENCHYMAL STEM CELLS, BY REGION, 2022-2029 (USD MILLION)133

TABLE 711GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MESENCHYMAL STEM CELLS, BY COUNTRY, 2022-2029 (USD MILLION)134

91AUTOLOGOUS STEM-CELL & NON-STEM CELL THERAPIES MARKET, BY END USER135

9.11INTRODUCTION136

TABLE 721AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022-2029 (USD MILLION)136

9.21HOSPITALS AND CLINICS136

9.2.11ABILITY TO UNDERTAKE APHERESIS PROCEDURES WITH ADVANCED HEALTHCARE INFRASTRUCTURE TO DRIVE MARKET136

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 73	AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2022-2029 (USD MILLION)	137
TABLE 74	NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)	137
TABLE 75	EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)	138
TABLE 76	ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)	138
TABLE 77	LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)	139
TABLE 78	MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2022-2029 (USD MILLION)	139
TABLE 79	GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)	139
9.3	LONG-TERM CARE FACILITIES	140
9.3.1	RIISING INCIDENCE OF CHRONIC DISEASES TO SUPPORT MARKET GROWTH	140
TABLE 80	AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2022-2029 (USD MILLION)	140
TABLE 81	NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022-2029 (USD MILLION)	141
TABLE 82	EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022-2029 (USD MILLION)	141
TABLE 83	ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022-2029 (USD MILLION)	141
TABLE 84	LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022-2029 (USD MILLION)	142
TABLE 85	MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2022-2029 (USD MILLION)	142
TABLE 86	GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022-2029 (USD MILLION)	142
9.4	SPECIALTY CARE CENTERS	143
9.4.1	GROWING PREFERENCE FOR PERSONALIZED MEDICINE TO BOOST DEMAND	143
TABLE 87	AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR SPECIALTY CARE CENTERS, BY REGION, 2022-2029 (USD MILLION)	143
TABLE 88	NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL FOR SPECIALTY CARE CENTERS, BY COUNTRY, 2022-2029 (USD MILLION)	144
TABLE 89	EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR SPECIALTY CARE CENTERS, BY COUNTRY, 2022-2029 (USD MILLION)	144
TABLE 90	ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR SPECIALTY CARE CENTERS, BY COUNTRY, 2022-2029 (USD MILLION)	144
TABLE 91	LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR SPECIALTY CARE CENTERS, BY COUNTRY, 2022-2029 (USD MILLION)	145
TABLE 92	MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR SPECIALTY CARE CENTERS, BY REGION, 2022-2029 (USD MILLION)	145
TABLE 93	GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR SPECIALTY CARE CENTERS, BY COUNTRY, 2022-2029 (USD MILLION)	145
10	AUTOLOGOUS STEM CELL AND NON-STEM STEM CELL THERAPIES MARKET, BY REGION	146

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

10.1 INTRODUCTION 147

TABLE 94 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY REGION, 2022-2029 (USD MILLION) 147

10.2 NORTH AMERICA 147

10.2.1 NORTH AMERICA: RECESSION IMPACT 147

FIGURE 31 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SNAPSHOT 148

TABLE 95 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 149

TABLE 96 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION) 149

TABLE 97 NORTH AMERICA: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION) 149

TABLE 98 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022-2029 (USD MILLION) 150

TABLE 99 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022-2029 (USD MILLION) 150

TABLE 100 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022-2029 (USD MILLION) 150

10.2.2 US 151

10.2.2.1 Rising R&D activities for stem cell therapies to drive market 151

TABLE 101 US: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION) 151

TABLE 102 US: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION) 152

TABLE 103 US: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022-2029 (USD MILLION) 152

TABLE 104 US: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022-2029 (USD MILLION) 152

TABLE 105 US: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022-2029 (USD MILLION) 153

10.2.3 CANADA 153

10.2.3.1 Rising government initiatives for regenerative medicine research to drive market 153

TABLE 106 CANADA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION) 154

TABLE 107 CANADA: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION) 154

TABLE 108 CANADA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022-2029 (USD MILLION) 154

TABLE 109 CANADA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022-2029 (USD MILLION) 155

TABLE 110 CANADA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022-2029 (USD MILLION) 155

10.3 EUROPE 155

10.3.1 EUROPE: RECESSION IMPACT 156

TABLE 111 EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 156

TABLE 112 EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION) 157

TABLE 113 EUROPE: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION) 157

TABLE 114 EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022-2029 (USD MILLION) 157

TABLE 115 EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022-2029 (USD MILLION) 158

TABLE 116 EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022-2029 (USD MILLION) 158

10.3.2 GERMANY 158

10.3.2.1 Rising focus on clinical research to drive market 158

TABLE 117 GERMANY: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION) 159

TABLE 118 GERMANY: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION) 159

TABLE 119 GERMANY: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022-2029 (USD

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

MILLION)159

TABLE 120GERMANY: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022-2029 (USD MILLION)160

TABLE 121GERMANY: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022-2029 (USD MILLION)160

10.3.3UK160

10.3.3.1Rising technological advancements in automation to drive market160

TABLE 122UK: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)161

TABLE 123UK: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)161

TABLE 124UK: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022-2029 (USD MILLION)162

TABLE 125UK: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022-2029 (USD MILLION)162

TABLE 126UK: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022-2029 (USD MILLION)162

10.3.4FRANCE163

10.3.4.1Growing focus on cell & gene therapy initiatives to boost demand163

TABLE 127FRANCE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)163

TABLE 128FRANCE: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)163

TABLE 129FRANCE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022-2029 (USD MILLION)164

TABLE 130FRANCE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022-2029 (USD MILLION)164

TABLE 131FRANCE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022-2029 (USD MILLION)164

10.3.5ITALY165

10.3.5.1Growth in biotech sector to drive market165

TABLE 132ITALY: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)165

TABLE 133ITALY: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)165

TABLE 134ITALY: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022-2029 (USD MILLION)166

TABLE 135ITALY: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022-2029 (USD MILLION)166

TABLE 136ITALY: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022-2029 (USD MILLION)166

10.3.6SPAIN167

10.3.6.1Rising focus on stem cell banking to support market growth167

TABLE 137SPAIN: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)167

TABLE 138SPAIN: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)167

TABLE 139SPAIN: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022-2029 (USD MILLION)168

TABLE 140SPAIN: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022-2029 (USD MILLION)168

TABLE 141SPAIN: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022-2029 (USD MILLION)168

10.3.7REST OF EUROPE169

TABLE 142REST OF EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)169

TABLE 143REST OF EUROPE: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)169

TABLE 144REST OF EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022-2029 (USD MILLION)170

TABLE 145REST OF EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022-2029 (USD MILLION)170

TABLE 146REST OF EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022-2029 (USD MILLION)170

10.4ASIA PACIFIC171

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

10.4.1 ASIA PACIFIC: RECESSION IMPACT 171

FIGURE 32 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SNAPSHOT 172

TABLE 147 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 173

TABLE 148 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION) 173

TABLE 149 ASIA PACIFIC: AUTOLOGOUS NON-STEM CELL THERAPIES, BY TYPE, 2022-2029 (USD MILLION) 173

TABLE 150 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022-2029 (USD MILLION) 174

TABLE 151 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022-2029 (USD MILLION) 174

TABLE 152 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022-2029 (USD MILLION) 174

10.4.2 JAPAN 175

10.4.2.1 Increasing product approvals to drive market 175

TABLE 153 JAPAN: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION) 175

TABLE 154 JAPAN: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION) 176

TABLE 155 JAPAN: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022-2029 (USD MILLION) 176

TABLE 156 JAPAN: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022-2029 (USD MILLION) 176

TABLE 157 JAPAN: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022-2029 (USD MILLION) 177

10.4.3 CHINA 177

10.4.3.1 Rising number of CAR T-cell clinical trials to support market growth 177

TABLE 158 CHINA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION) 178

TABLE 159 CHINA: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION) 178

TABLE 160 CHINA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022-2029 (USD MILLION) 178

TABLE 161 CHINA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022-2029 (USD MILLION) 179

TABLE 162 CHINA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022-2029 (USD MILLION) 179

10.4.4 INDIA 179

10.4.4.1 Rising incidence of cancer and growing focus on product commercialization to boost demand 179

TABLE 163 INDIA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION) 180

TABLE 164 INDIA: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION) 180

TABLE 165 INDIA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022-2029 (USD MILLION) 180

TABLE 166 INDIA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022-2029 (USD MILLION) 181

TABLE 167 INDIA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022-2029 (USD MILLION) 181

10.4.5 SOUTH KOREA 181

10.4.5.1 Rising growth in biopharmaceutical industry to drive market 181

TABLE 168 SOUTH KOREA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION) 182

TABLE 169 SOUTH KOREA: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION) 182

TABLE 170 SOUTH KOREA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022-2029 (USD MILLION) 183

TABLE 171 SOUTH KOREA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022-2029 (USD MILLION) 183

TABLE 172 SOUTH KOREA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022-2029 (USD MILLION) 183

10.4.6 REST OF ASIA PACIFIC 184

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 173☐REST OF ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)☐184

TABLE 174☐REST OF ASIA PACIFIC: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)☐184

TABLE 175☐REST OF ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022-2029 (USD MILLION)☐185

TABLE 176☐REST OF ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022-2029 (USD MILLION)☐185

TABLE 177☐REST OF ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022-2029 (USD MILLION)☐185

Autologous Stem Cell & Non-stem Cell Therapies Market by Type (CAR-T, Tumor Infiltrating Lymphocyte), Indication (Cancer, Musculoskeletal, Dermatology), Source (T-Cells, Mesenchymal Stem Cell), End User (Hospital) - Global Forecast to 2029

Market Report | 2024-06-07 | 295 pages | MarketsandMarkets

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Date

2025-06-25

Signature



Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com